Cabometyx is under clinical development by Exelixis and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cabometyx’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cabozantinib s-malate (Cabometyx, Aptimetyx) is a s-malate salt form of cabozantinib, acts as an anti-neoplastic agnet. It is formulated as film-coated tablets for oral route of administration. Cabometyx is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible. Cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.
The drug candidate is under development for solid tumors, undifferentiated pleomorphic sarcoma, Recurrent and metastatic esophageal squamous cell carcinoma, neuroendocrine gastroenteropancreatic tumors (GEP-NET), neuroendocrine neoplasia, neuroendocrine carcinoma, metastatic hormone sensitive prostate cancer, muscle-invasive bladder cancer, poorly-differentiated neuroendocrine carcinomas, metastatic cervical cancer, adenocarcinoma of the prostate, Ewing sarcoma, microphthalmia transcription factor associated sts (alveolar soft part sarcoma [asps] and clear cell sarcoma [ccs]), hepatocellular carcinoma, differentiated thyroid cancer, salivary gland cancer, gastrointestinal stromal tumor (GIST), non-small cell lung carcinoma, high-grade glioma, transitional cell cancer (urothelial cell cancer), metastatic HER2 negative, HER2 positive, triple-negative breast cancer, soft tissue sarcoma, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, epithelial ovarian cancer, endometrial cancer, gastric cancer, peritoneal cancer, fallopian tube cancer, transitional cell carcinoma (urothelial cell carcinoma), esophageal cancer, lymphoma, leukemia, gastroesophageal (GE) junction carcinomas, metastatic colorectal cancer, germ cell tumor, head and neck cancer and malignant melanoma, non-colon gastrointestinal cancers including hepatobiliary, pancreatic, and gastroesophageal tumors and upper aerodigestive tract cancers including lip, tongue, gum, oral cavity, mouth, tonsils, oropharynx, nasopharynx, nasal cavity, sinus, and larynx tumors.
It was also under development for the treatment of relapsed/refractory multiple myeloma, salivary gland, cancer and adenoid cystic carcinoma (ACC).
Exelixis is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include, Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). The company’s pipeline product candidates include XL092 for the treatment of advanced solid malignancies and XL888, an ATP-competitive inhibitor of HSP90, and others. The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in Alameda, California, the US.
For a complete picture of Cabometyx’s drug-specific PTSR and LoA scores, buy the report here.